COMPASS Sets Course For J&J/Bayer's Xarelto In Unexplored Indications

 
• By Alexandra Shimmings

A large new market in coronary artery and peripheral arterial disease beckons after Xarelto showed a 24% reduction in the risk of major cardiac events, a benefit that may outweigh the increase in major bleeding.

Antique bronze emblem compass, mini compass necklace pendant and binocular telescopes on ancient world map. (vintage style)
COMPASS Pointns The Way To New Sales Territory • Source: Shutterstock

BARCELONA – Janssen Pharmaceuticals Inc. and Bayer AG will make an assault on the largely uncaptured market of coronary artery and peripheral arterial disease patients after the 27,000-patient COMPASS study showed that their Factor Xa inhibitor Xarelto (rivaroxaban) as an add-on to aspirin therapy reduced the risk of major adverse cardiovascular events compared to aspirin alone.

Full data for COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) in coronary artery disease (CAD) and peripheral arterial disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.